Intellia TherapeuticsNTLA
Price$12.12Intrinsic value$33.24174% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $59.5M+2.8% YoYTTM through 30 Jun 2026
Net Income -$400MTTM through 30 Jun 2026
Free Cash Flow -$348.7MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-696.4%
Operating Margin-711.7%
Net Margin-672.2%

Returns

-55.0%ROE
-46.7%ROA

Balance Sheet Health

Current Ratio6.65x
Cash & Equivalents$106.1M

Quality Metrics

Altman Z-Score2.75
Piotroski F-Score3 / 9
FCF Margin-586.0%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $67.7M
Diluted EPS-$3.34TTM
'20'21'22'23'24'25
FY2025: $-3.81

Dividend

No dividend

Capital Allocation

Capex Intensity3.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.